Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NAAA | Q02083 | 2/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL609220 | 0.80 | PDE4B (0.37) | KMT2A | |
| SCHEMBL16414502 | 0.80 | LIPG (0.42) | TAAR1KMT2ANAMPTLIPG | |
| SCHEMBL22835940 | 0.80 | LIPG (0.42) | TAAR1KMT2ANAMPTLIPG | |
| SCHEMBL22835620 | 0.80 | LIPG (0.42) | TAAR1KMT2ANAMPTLIPG | |
| SCHEMBL2898018 | 0.79 | LIPG (0.36) | TAAR1NAMPTLIPG | |
| SCHEMBL18669362 | 0.79 | DPP7 (0.37) | TAAR1NAMPTLIPG | |
| SCHEMBL18426120 | 0.78 | KMT2A (0.42) | TAAR1KMT2ALIPG | |
| SCHEMBL18426119 | 0.78 | KMT2A (0.42) | TAAR1KMT2ALIPG | |
| SCHEMBL2146187 | 0.76 | TAAR1 (0.36) | TAAR1KMT2ANAMPTLIPG | |
| SCHEMBL28872292 | 0.76 | ALDH1A1 (0.38) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633717-B1 | P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | ASTRAZENECA AB (SE) | 2009-10-28 | — | — | EP | disclosed |
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | ASTRAZENECA AB (SE) | 2009-06-04 | — | — | US | disclosed |
| US-7408065-B2 | P2X7 receptor antagonists and their use | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-20060293337-A1 | P2x7 receptor antagonists and their use | ASTRAZENECA AB (SE) | 2006-12-28 | — | — | US | disclosed |
| EP-1633717-A1 | NEW P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | AstraZeneca AB (SE) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004106305-A1 | NEW P2X7 RECEPTOR ANTAGONISTS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293337-A1 | P2x7 receptor antagonists and their use | P2RX7, P2RX1, P2RX2 | TAAR1 385/4885USP30 4278/4885KMT2A 3924/4885 |
| US-20090143354-A1 | P2X7 Receptor Antagonists and Their Use | P2RX7, P2RX1, P2RX2 | TAAR1 385/4885USP30 4278/4885KMT2A 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.